Breaking News
More () »

St. Louis biotech startup Precision Virologics acquires rights for COVID-19 vaccine

Precision Virologics and Bharat Biotech, based in India, have acquired rights for a novel chimp-adenovirus vaccine for COVID-19
Credit: SLBJ
David Curiel, interim CEO of Precision Virologics

ST. LOUIS — A St. Louis-based biotech startup, along with a firm based in India, have licensed a COVID-19 vaccine candidate from the Washington University School of Medicine. 

Precision Virologics and Bharat Biotech, based in India, have acquired rights for a novel chimp-adenovirus vaccine for COVID-19, which is based on a common-cold virus that affects chimpanzees. As part of the deal, St. Louis-based Precision has obtained rights for the vaccine in the U.S., Europe and Japan. Bharat’s licensing includes rights to distribute the vaccine in all other global markets. 

The companies said their licensing deals will advance the development and manufacturing of the vaccine technology, which was developed by Washington University Professors David Curiel and Michael Diamond.

Curiel is interim CEO of Precision and Diamond is the startup’s scientific adviser. Precision is a vaccine startup that launched about three years ago with a focus on emerging infectious diseases. The company is also advancing vaccine development for influenza, Zika virus and chikungunya. BioGenerator, the investment arm of innovation hub BioSTL, helped launch Precision and operates intellectual property rights and business negotiations for the firm.

The vaccine licensed by Precision and Bharat would be distributed through a nasal spray, which Curiel said is a key differentiator from other vaccine candidates being developed by biotechnology companies. Curiel said mouse studies of the vaccine provided “surprising results,” specifically that a single dose provided full protection and sterilized the upper respiratory tract. 

"The ability to accomplish effective immunization with a single nasal dose is a major advantage, offering broader reach and easier administration," he said. "An effective nasal dose not only protects against COVID-19, but it also prevents the spread of the disease by directly targeting the cells that line the nose and throat. Most other vaccine candidates currently under development can't do that.”

The company’s findings were published in scientific journal Cell, which led Bharat to inquire about licensing the vaccine. 

Click here for the full story.

Paid Advertisement